RADIOLOGICAL OR NUCLEAR MEDICAL COUNTERMEASURE PRODUCT DEVELOPMENT SUPPORT (PDS)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), intends to solicit proposals for a contract titled "Radiological or Nuclear Medical Countermeasure Product Development Support (PDS)". The primary objective is to advance the development of candidate medical countermeasures (MCMs), including biodosimetric approaches, for acute radiation syndrome (ARS) or delayed effects of acute radiation exposure (DEARE), aiming for eventual FDA approval or licensure. This will be an Indefinite Delivery, Indefinite Quantity (IDIQ) contract with a 7-year period of performance.
Scope of Work
The selected contractor will support the advancement of candidate MCMs through various development stages, from early research to post-marketing. This involves collaboration with NIAID and other federal authorities like the FDA. Key task areas include:
- Administrative and Technical Support
- Animal Model and New Approach Methodologies (NAMs) Development
- Efficacy Testing of Candidate MCMs
- Non-Clinical Studies for IND/NDA/BLA Submissions
- Chemistry, Manufacturing and Control (CMC) Support
- Phase I Clinical Studies and Support
Contract & Timeline
- Contract Type: Indefinite Delivery, Indefinite Quantity (IDIQ)
- Period of Performance: 7 years, beginning on or about July 1, 2027
- Anticipated Award Date: July 1, 2027
- RFP Availability: On or about June 2, 2026, via SAM.gov
- Response Date: June 2, 2026 (RFP availability date, not proposal due date)
- Published Date: May 18, 2026
Set-Aside
- None specified in this presolicitation notice.
Evaluation Factors
Proposals will be evaluated based on:
- Comprehensiveness, soundness, adequacy, and suitability of the proposed scientific approach and methodology.
- Organizational capabilities, experience, and understanding of MCM development against radiological and nuclear agents.
- Adequacy of scientific and technical personnel, facilities, equipment.
- Compliance with Good Laboratory Practice (GLP), current Good Manufacturing Practice (cGMP), and Good Clinical Practice (GCP).
- Project management.
Submission Details
Proposals must be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website (https://ecps.nih.gov/). Facsimile or email submissions are not acceptable.
Additional Notes
This is a presolicitation notice and does not commit the Government to award a contract. The place of performance is currently unknown. No collect calls or facsimile transmissions will be accepted.